OHSU Innovates

OHSU innovators

Graphic of lightbulb inside a head. Image courtesy of Getty Images

Tell us about a new idea or technology and learn how OHSU could help protect the intellectual property.

Startup support

Graphic of seedling. Image courtesy of Getty Images

Interested in forming a new company around your idea? Learn about how OHSU can help with startup company formation.

Collaborations

Graphic of two hands shaking. Image courtesy of Getty Images

Learn more about existing OHSU partnerships and opportunities to work with OHSU community members.

Licensing opportunities

Green icon of lightbulb with circular arrows. Image courtesy of Getty Images

Visit the OHSU Technology Portal to search for existing licensing opportunities and review technology summaries.

Agreements

Red icons of a clipboard with a path. Image courtesy of Getty Images

Learn more about academic and industry agreements including material transfer agreements (MTAs) and more.

Entrepreneurial education

Green icon of thought-bubble over three people. Image courtesy of Getty Images

Learn more about OHSU curriculum and programs offered to provide entrepreneurial training to OHSU members.

OHSU Innovates collaborative network

OHSU Innovates 2022 Impact Report

The OHSU Innovates 2022 Impact Report provides a snapshot of the successes that come from innovative science, academic-industry collaborations and an infrastructure that stewards ideas to impact.

You’ll find numbers that show the impact of funding great ideas, and you’ll see profiles of some of the innovators and start-ups that demonstrate the change that innovation can bring. The report also shares services and resources we provide to help build a vibrant entrepreneurial ecosystem. Read the full report.

Featured news

OHSU startup company announces initiation of a phase 1 clinical trial for the treatment for major depressive disorder

OHSU startup company, Autobahn Therapeutics, recently announced the initiation of its first phase 1 clinical trial of ABX-002 for major depressive disorder. The ABX-002 study drug is a brain-boosting thyroid receptor beta (TRβ) agonist, which has the potential to augment antidepressant treatments to improve patient responsiveness to these drugs. ABX-002 was designed and first synthesized and evaluated at OHSU by a team of researchers that included Tom Scanlan, Ph.D., Ben Emery, Ph.D., and Dennis Bourdette, M.D.

Read more about the initiation of the Phase 1 trial in the press release.

See more news

Featured event

Event information for Life Sciences Washington-BMS VIP Forum

VIP Forum with Bristol Myers Squibb

Life Science Washington Institute will be hosting a Venture Investment & Partnering Forum on February 13 & 14 with Bristol Myers Squibb (BMS). There are two ways to participate in this event:

1) RSVP to the Plenary Session and Networking Reception (No cost to attend!)

2) Apply to meet with BMS representatives (deadline December 9)

BMS partners with companies with innovative technologies, products, and therapies that accelerate growth and advance patient care. BMS is looking to meet with companies and researchers in specific areas of focus to discuss potential collaborations, partnerships, investment, licensing opportunities, and M&A.

Learn more at the event webpage.

See more events

Featured innovation

Innovative Technology Series – Casey Reading Center

The Casey Reading Center, which is part of the Casey Eye Institute, works with clinical partners and sponsors to help advance new treatments for patients with eye diseases. The Casey Reading Center uses innovative software developed at OHSU to provide customized and advanced ophthalmic research to its partners. Learn more about the center by visiting their website.

See more innovations